Clinical Genomicist WorkSpace (CGW)

WELCOME TO YOUR WORKSPACE.

Streamlined Integrated Workflow

The Clinical Genomicist Workspace (CGW) is our comprehensive environment that will accelerate your ability to offer Next Generation Sequencing-based clinical tests. Our cloud-based single workspace solution seamlessly manages data and clinical workflow for each patient case:

  • Sequencing: primary data are acquired from sequencers to start the analytical process

  • Analysis: variants are called and annotated using validated pipelines and comprehensive genomic databases

  • Draft Report: medical interpretations and just-in-time curated information from our rapidly expanding medical knowledgebase are processed through a proprietary algorithm, which then produces a report highlighting the most relevant, clinically actionable information

  • Final Report: a fully featured, online editing system allows the medical professional to review, finalize, and sign out a report

  • Integration in Electronic Health Record: signed out report is messaged to the medical record for review by the treating physician



Gateway Lab Services

ACCELERATING YOUR TESTING PORTFOLIO

The PierianDx’S Gateway Lab Services allows you to access and customize a range of assays right out of the box. This service delivers clinically validated Next-Generation Sequencing (NGS) tests for a range of cancers and inherited diseases. Gateway Lab Services allows you to:

  • Enhances your brand by making personalized medicine your competitive advantage

  • Eases transition into fully-integrated NGS lab capabilities

  • Expend no capital outlay to get started

  • Provides speed to market – you focus on your long-term NGS testing strategy while we help you implement today


GATEWAY PROGRAM ASSAYS

OncoComplete is the most comprehensive somatic cancer assay available on the market with the ability to deeply interrogate cancer-associated genes, provide broad coverage across the entire coding region, and ensure long tail of cancer mutations are identified.

Learn More

This is a pan cancer assay encompassing 160 cancer related genes and 126 gene fusions. Additionally, new hematologic malignancy profiles have been introduced for myeloid neoplasms and lymphoid neoplasms respectively.

The benefits of high-throughput sequencing include: smaller input DNA requirements, greater sensitivity/specificity, advanced bioinformatics processing and rapid turn-around time.

Professional Services

WE’VE GOT YOUR BACK

PierianDx’s Professional Services ensure that you have everything you need to effectively manage the clinical NGS workflow and can begin case sign-out as rapidly as possible. Our team of genomicists can help you with everything from designing your own NGS testing strategy to final implementation of custom assays. We can help you design and validate your own custom gene panels and pipelines, set up your own CLIA-certified lab, and develop a comprehensive validation plan for each panel. Our professional services allows you to:

  • Accelerate your personalized medicine initiatives

  • Ease transition into fully-integrated NGS lab capabilities

  • Provide flexible engagement services designed around your needs

  • Leverage years of experience and best practices


Interpretation Services

PierianDx interpretation services includes a team of medical directors and variant scientists that leverage technology to assist CGW customers during implementation or as add-on service. Our interpretation services cover the full range of gene tests for inherited conditions and somatic cancer, and can be customized in three ways:

  • PDx variant analysis with your medical director performing review and sign out

  • PDx variant analysis, case preparation and medical review with your sign-out

  • PDx performs the entire service including variant analysis, case preparation, medical review and sign out


  • “Our partnership with PierianDx will supply healthcare systems’ in-house labs with a simpler and more integrated workflow. The PierianDx bioinformatics platform and testing services will ultimately speed the delivery of precision care to patients.”

    Jonathan Hirsch, Founder & President of Syapse